{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-23-000048","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.071306+00:00","generated_at":"2026-06-12T07:07:09.377484+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PTC Therapeutics Q2 revenue $214M (+29% YoY); raises full-year guidance to $940M-$1.0B","bullets":["Total revenue $213.8M vs $165.5M Q2 2022; DMD franchise $162M (+21%).","Translarna net revenue $96.5M; Emflaza $65.7M; Evrysdi royalties $36.9M.","Sepiapterin APHENITY trial met primary endpoint; NDA filing planned Q4 2023.","GAAP net loss $198.9M; cash $337.9M; gene therapy discontinues caused $88M non-cash charge.","Full-year 2023 total revenue guidance raised to $940M-$1.0B; DMD product revenue guidance $545-$575M."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-23-000048","json":"https://secwatch.observer/filing/0001070081-23-000048.json","markdown":"https://secwatch.observer/filing/0001070081-23-000048.md","text":"https://secwatch.observer/filing/0001070081-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000048/0001070081-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000048/tmb-20230803x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:07:09.377484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80159f52f1a3ef2f544aaad0040e9809d0d35d1c","claim":"PTC THERAPEUTICS, INC. reported financial results for the second quarter ending June 30, 2023.","evidence_excerpt":"On August 3, 2023, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000048/0001070081-23-000048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ending June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}